0
Cover       Event-at-a-Glance                  Our Sponsors       Hotel & Travel                     Short Courses        ...
Cover       Event-at-a-Glance                  Our Sponsors                                                              C...
Cover                                                              short courses*                                         ...
Cover                                                              short courses* (continued)       Event-at-a-Glance     ...
Cover                                                                                                                     ...
Cover                                                    15th Annual                                                      ...
Cover                                                                14th Annual                                          ...
Cover                                                                4th Annual                                           ...
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Antibodies for Cancer Therapy
Upcoming SlideShare
Loading in...5
×

Antibodies for Cancer Therapy

1,010

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,010
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
15
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Antibodies for Cancer Therapy"

  1. 1. Cover Event-at-a-Glance Our Sponsors Hotel & Travel Short Courses April 29 - May 3, 2013 seaport world trade center Boston, MA Biologics Partnering forum PHARMA-BIO PARTNERING FORUMS engineering streamFocusing on the Right Partners Phage and Yeast Display Engineering Antibodies Engineering Bispecific Antibodies Register by March 22 oncology stream and save up to $200! Antibodies for Cancer Therapy Bispecific Antibodies for Oncology Antibody-Drug Conjugates expression stream Difficult to Express Proteins Optimizing Protein Expression High-Throughput Protein Expression analytical stream Characterization of Biotherapeutics Biophysical Analysis of Biotherapeutics Protein Aggregation and Stability safety stream Immunogenicity for Regulatory Success Immunogenicity Prediction & Mitigation PK/PD of Antibody-Derived Molecules purification stream premier sponsors Purifying Antibodies and Recombinant Proteins Protein Aggregation and Stability Sponsor & Exhibit Registration Organized by Cambridge Healthtech Institute PEGSummit.com
  2. 2. Cover Event-at-a-Glance Our Sponsors Conference-at-a-Glance event-at-a-glance Hotel & Travel Short Courses Engineering Oncology Expression Analytical Safety Purification Biologics Stream Stream Stream Stream Stream Stream Partnering Biologics Partnering forum forum PHARMA-BIO PARTNERING FORUMS Sunday Pre-Conference Short Courses* engineering streamFocusing on the Right Partners April 28 Phage and Yeast Display Monday Phage and Yeast Antibodies for Difficult to Express Characterization of Immunogenicity for Biologics April 29 Display Cancer Therapy Proteins Biotherapeutics Regulatory Success PHARMA-BIO Partnering Engineering Antibodies PARTNERING FORUMS Tuesday Phage and Yeast Antibodies for Difficult to Express Characterization of Immunogenicity for Biologics Focusing on the Right Partners Engineering Bispecific Antibodies April 30 Display Cancer Therapy Proteins Biotherapeutics Regulatory Success PHARMA-BIO Partnering PARTNERING FORUMS Plenary Panel Discussion Focusing on the Right Partners oncology stream Dinner Short Courses* Antibodies for Cancer Therapy Wednesday Engineering Advancing Bispecific Optimizing Protein Biophysical Immunogenicity Purifying Antibod- May 1 Antibodies Antibodies to the Expression Analysis of Prediction and ies & Recombinant Clinic for Oncology Biotherapeutics Mitigation Proteins Bispecific Antibodies for Oncology Thursday Engineering Advancing Bispecific Optimizing Protein Biophysical Immunogenicity Purifying Antibod- Antibody-Drug Conjugates May 2 (am) Antibodies Antibodies to the Expression Analysis of Prediction and ies & Recombinant Clinic for Oncology Biotherapeutics Mitigation Proteins expression stream Thursday Engineering Bispe- Antibody-Drug Con- High-Throughput Protein Aggregation PK/PD of Antibody- Protein Aggregation May 2 (pm) cific jugates Protein Expres- and Stability in Derived Molecules and Stability in Antibodies sion Biopharmaceuticals Biopharmaceuticals Difficult to Express Proteins Dinner Short Courses* Optimizing Protein Expression Friday Engineering Bispe- Antibody-Drug Con- High-Throughput Protein Aggregation PK/PD of Antibody- Protein Aggregation May 3 cific jugates Protein Expres- and Stability in Derived Molecules and Stability in High-Throughput Protein Expression Antibodies sion Biopharmaceuticals Biopharmaceuticals *Separate Registration Required. analytical stream Characterization of Biotherapeutics Biophysical Analysis of Biotherapeutics Plenary Keynote Panel Protein Aggregation and Stability Tuesday April 30, 2013 , 4:15 – 5:30 pm Panelists: safety stream Conventional vs. Non-Conventional Formats David Meininger, Ph.D., MBA, Executive Director, Molecular Discovery, Merck Immunogenicity for Regulatory Success Moderator: Janice Reichert, Ph.D., Editor-in-Chief, mAbs; Managing Director, Reichert Biotechnology Consulting LLC Immunogenicity Prediction & Mitigation With the explosion in the number of formats available, Tillman Gerngross, Ph.D., CEO and Co-Founder, Adimab what are the potential benefits and risks to patients? This LLC; Professor, Bioengineering, Thayer School of PK/PD of Antibody-Derived Molecules panel will discuss the realistic outlook and uncertainties Engineering, Dartmouth College with developing a diverse array of non-canonical antibodies in terms purification stream of immunogenicity, safety, competitive marketplace, commercial development, business strategies, regulatory approval, target Trudi Veldman, Ph.D., Senior Director, Biologics Generation, Purifying Antibodies and Recombinant Proteins validation and clinical development. AbbVie Protein Aggregation and Stability Sponsor & Exhibit Registration Organized by Cambridge Healthtech Institute 2 PEGSummit.com
  3. 3. Cover short courses* our sponsors Event-at-a-Glance Our Sponsors Sunday, April 28, 2013 (SC4) Translational Considerations for Development of Monoclonal Antibodies Part I: premier sponsors Hotel & Travel Short Courses Morning Courses | 10:00 am – 1:00 pm Focus on Early Discovery Chair: Mohammad Tabrizi, Ph.D., Head, PK/PD & Senior (SC1) Antibody Humanization via One Hot Fellow, Merck Homology Model – Hands-On Workshop Instructors: Gadi Bornstein, Ph.D., Associate Research Biologics Partnering forum Instructor: Vinodh Kurella, Ph.D., Visiting Research PHARMA-BIO Fellow, Centers for Therapeutic Innovation, Pfizer Inc. PARTNERING Fellow, FORUMS Scott L. Klakamp, Ph.D., Principal Consultant, SKD corporate sponsors engineering streamFocusing on the Right Partners Harvard Medical School Consulting LLC • Create an antibody homology model from the Randall Brezski, Ph.D., Senior Research Scientist, mouse/rat/rabbit primary sequence Phage and Yeast Display Biotechnology Center of Excellence, Janssen R&D, Inc. • Humanization strategies based on the antibody • Considerations for target selection, antibody homology model screening and mAb preclinical development Engineering Antibodies • Steric clashes within the humanized antibody and • Antibody affinity and biophysical characterization: rational methods to fix it Biacore, Kinexa, and FACS Engineering Bispecific Antibodies • Affinity maturation of the humanized antibody • Application of antibody engineering in All materials, including tutorials/exercises and the development of next generation scripts, will be available for users during and after the antibody-based therapeutics oncology stream workshop. No prior programming experience necessary. Please bring your laptop for the workshop. Afternoon Courses | 2:00 – 5:00 pm Antibodies for Cancer Therapy (SC2) Basics of Immunogenicity (SC5) Biosimilars & Biobetters: Development, Instructors: Jim McNally, Ph.D., Senior Principal Regulation and Prospects Bispecific Antibodies for Oncology Scientist, Chair: Zahra Shahrokh, Consultant, CMC, ZDev Pfizer, Inc. Consulting Darshani Jani, Ph.D., Senior Associate Scientist, R&D, Instructors: Steven A. Grossman, J.D., Public Policy and Antibody-Drug Conjugates Biogen Idec, Inc. FDA Regulatory Consultant, HPS Group, LLC • Basic issues regarding screening, confirmatory and Carolyn C. Huntenburg, Ph.D., Vice President, titer assays Regulatory Affairs, Momenta Pharmaceuticals expression stream • Assay methodologies and various technologies Magdalena Leszczyniecka, Ph.D., MBA, President and MT • Current approaches to data analysis and cutpoints CEO, STC Biologics, Inc. Difficult to Express Proteins • Preclinical and clinical considerations • Regulatory guidelines & issues • Common problems • Case studies Optimizing Protein Expression • Developing biosimilars/biobetters (SC3) Phage and Yeast Display Libraries • Unique requirements Instructors: Andrew M. Bradbury, M.B., B.S., Ph.D., High-Throughput Protein Expression Staff Scientist, Biosciences, Los Alamos National (SC6) Overcoming the Challenges of Laboratory Immunogenicity Assessment James D. Marks, M.D., Ph.D., Professor, Anesthesia Instructors: Jim McNally, Ph.D., Senior Principal analytical stream & Pharmaceutical Chemistry, UC, San Francisco; Scientist,Pfizer, Inc. Chief, Anesthesia and Vice Chairman, Anesthesia & Darshani Jani, Ph.D., Senior Associate Scientist, R&D, Characterization of Biotherapeutics Perioperative Care, San Francisco General Hospital Biogen Idec, Inc. • Phage display and construction of phage-displayed • Challenges and approaches to resolve commonly scFv and Fab libraries Biophysical Analysis of Biotherapeutics encountered issues • Yeast display and construction of yeast-displayed • Emerging trends in the development of neutralizing scFv and Fab libraries antibody assays Protein Aggregation and Stability • Selection and screening technologies that are • Cross reactivity to endogenous proteins compatible with phage and yeast-display libraries • Clinical implications of ADAs • Combining phage and yeast display for antibody safety stream selection and epitope identification *Separate Registration Required. Immunogenicity for Regulatory Success Immunogenicity Prediction & Mitigation Poster Discount Gain further exposure by presenting your work in the poster sessions. corporate support sponsors PK/PD of Antibody-Derived Molecules • Your poster will be exposed to our international delegation • Receive $50 off your registration • Your poster abstract will be published in our conference materials purification stream • Your research will be seen by leaders from top pharmaceutical, biotech, academic and government institutes Purifying Antibodies and Recombinant Proteins • Poster competition To secure a poster board and inclusion in the conference materials, your abstract must be submitted, Protein Aggregation and Stability approved and your registration paid in full by March 22, 2013. Sponsor & Exhibit Registration Organized by Cambridge Healthtech Institute 3 PEGSummit.com
  4. 4. Cover short courses* (continued) Event-at-a-Glance Our Sponsors (SC7) Alternate Display Technologies (SC12) How to Obtain Reliable Information from Light Scattering: Theory, Practical Hotel & Travel Short Courses Instructors: John Löfblom, Ph.D., Assistant Professor, Molecular Biotechnology, AlbaNova University Advice and Data Interpretation Center, Royal Institute of Technology (KTH) Instructors: David Dolak, MBA, Product Manager, Light Scattering Technologies, Malvern Instruments Birgit Dreier, Ph.D., Senior Scientist, Laboratory of Prof. Dr. A. Plückthun, Department of Kevin Mattison, Ph.D., Principal Scientist, Bioanalytics, Malvern Instruments Biochemistry, University of Zurich Ulf Nobbmann, Ph.D., Product Manager, GPC/SEC Technologies, Malvern Instruments Biologics Partnering forum • Development of new display systems to address shortcomings of phage and yeast display Mark Pothecary, Ph.D., Product Manager, Light Scattering Products, Malvern Instruments PHARMA-BIO PARTNERING FORUMS • Constructing libraries and assessing library quality • Which key indicators assure reliable DLS & SEC-LS data quality? engineering streamFocusing on the Right Partners • Screening and selection methods for generation of new affinity proteins as well as for epitope • What are hydrodynamic size & polydispersity? mapping purposes • How is the mass distribution determined in DLS and how valid is it? Phage and Yeast Display • Coverage of bacterial display, E. coli display, and ribosome display • Is light scattering suitable for quality control applications? (SC8) Automated Antibody Sequencing Using Engineering Antibodies Mass Spectrometry THursday, May 2, 2013 Instructor: Natalie Castellana, Ph.D., CTO, Digital Proteomics, LLC Engineering Bispecific Antibodies • How to design a mass spectrometry experiment for antibody sequencing Dinner Short Courses | 5:30 – 7:30 pm • The available algorithms for sequencing focusing on Valens (SC13) Optimization of Formulation Viscosity in Concentrated • Trouble shooting poorly-sequenced areas by performing new experiments and mAb Solutions: Theory, Protein-Protein Interactions and Formulation Factors oncology stream tweaking parameters Instructors: Devendra (Davy) Kalonia, Ph.D., Professor, Pharmaceutical Sciences, University of (SC9) Translational Considerations for Development of Monoclonal Antibodies Part Connecticut Antibodies for Cancer Therapy II: Focus on Nonclinical Development to Clinic Sandeep Yadav, Ph.D., Scientist, Late Stage Product Development, Genentech, Inc. Chair: Mohammad Tabrizi, Ph.D., Head, PK/PD & Senior Fellow, Merck • Review of viscosity theory including specific volume, shape of the molecule, intrinsic viscosity, Bispecific Antibodies for Oncology Instructors: Cherryl Funelas, Bioanalytical Manager, Genentech electroviscous effects, and charge effects Isabel Figueroa, Associate Principal Scientist, PK/PD, Merck • Contribution of the solute, solvent and excipients to over viscosity of the solution • Protein-protein interactions and their effect on viscosity Antibody-Drug Conjugates • Considerations for immunoassay development in support of pharmacokinetic, immunogenicity & biomarker evaluation • Optimization of solution viscosity • Considerations for Development of Novel Antibody- Based Therapeutics (SC14) Antibody-Drug Conjugate Therapeutics: Potential and Challenges expression stream • Preclinical considerations, a science-based approach: Design goal, MOA, choice of species, and Instructors: Pam Trail, Ph.D., Vice President, Oncology, Regeneron Pharmaceuticals preclinical plans Jan Pinkas, Ph.D., Director, Pharmacology, ImmunoGen, Inc. Difficult to Express Proteins • Translation of exposure-response data from discovery into the clinic in support of FIH dosing Christopher D. Thanos, Ph.D., Director, Protein Engineering, Sutro Biopharma, Inc. Ho Sung-Cho, Ph.D., CTO, Ambrx, Inc Optimizing Protein Expression TUESday, April 30, 2013 • Target Selection for ADCs • Selection of the Antibody for a Target High-Throughput Protein Expression Dinner Short Courses | 6:00 – 8:00 pm • Cleavable Linkers (SC10) Immunogenicity Risk Assessment and Regulatory Strategy • Linker Modification & Resistance Instructors: Kathleen Clouse, Ph.D., Director, Division of Monoclonal Antibodies FDA/CDER • Overcoming Drug Resistance analytical stream Bridget Heelan, Ph.D., Clinical Assessor, Medicines and Healthcare Products Regulatory Agency • Novel Drugs and Payloads (MHRA) UK • Regulatory Issues Characterization of Biotherapeutics • Priorities for the regulator: Hierarchy of concerns; Data requirements; Common gaps • Integrated approach: Risk identification; Aligning identified risks with CMC; Bioanalytical, non- clinical and clinical strategy; Ongoing risk management Biophysical Analysis of Biotherapeutics • Interactive case study: Illustration of preparation of an effective response to a regulatory scenario pertaining to immunogenicity-related risks for an investigational therapeutic protein Protein Aggregation and Stability (SC11) Boosting Anti-Tumor Immunity with Monoclonal Antibodies Instructors: Wayne A. Marasco, M.D., Ph.D., Professor, Cancer Immunology and AIDS, Dana-Farber safety stream Cancer Institute; Professor of Medicine, Department of Medicine, Harvard Medical School Michael A. Postow, M.D., Medical Oncology Fellow, Memorial Sloan-Kettering Cancer Center Immunogenicity for Regulatory Success Lawrence J. Thomas, Ph.D., DABT, CMAR, Senior Director, Preclinical Research and Development, Celldex Therapeutics, Inc. Lauren Harshman, M.D., Assistant Professor, Dana-Farber Cancer Institute Immunogenicity Prediction & Mitigation • CTLA-4 blockade: Past, present, and future • Development of a human monoclonal antibody for potential therapy of CD27-expressing The Intro-Net offers you the opportunity to set up meetings with selected PK/PD of Antibody-Derived Molecules lymphoma and leukemia attendees before, during and after this conference, allowing you to connect • A Human anti-CCR4 monoclonal antibody with potent tumor cell killing and to the key people that you want to meet. This online system was designed immunomodulatory activities purification stream with your privacy in mind and is only available to registered session • Targeting the Programmed Death-1 (PD-1) Pathway in Renal Cell Carcinoma attendees of this event. Purifying Antibodies and Recombinant Proteins Protein Aggregation and Stability *Separate Registration Required. Sponsor & Exhibit Registration Organized by Cambridge Healthtech Institute 4 PEGSummit.com
  5. 5. Cover partnering forum Biologics Partnering Forum: Event-at-a-Glance Our Sponsors April 29-30, 2013 Hotel & Travel Short Courses PHARMA-BIO PHARMA-BIO PARTNERING Biologics Partnering forum PARTNERING FORUMS Antibody & Protein Engineering FORUMS Focusing on the Right Partners engineering streamFocusing on the Right Partners Program Advisors (as of November 30, 2012) PENTRA®: A Tissue-Penetrating Class of Antibodies for Dermatology and Other Diseases Phage and Yeast Display Brian Atwood, MBA, Managing Director, Versant Ventures Titus Kretzschmar, CSO, Delenex Therapeutics AG Daniel Blom, Director, Cardiovascular Diseases, Merck & Co. DutaMabs: A Novel Bi-specific Monoclonal Antibody Platform Engineering Antibodies Ray Camphausen, Ph.D., Associate Vice President, Protein Design, Adnexus, Bristol-Myers Squibb Kristian Jensen, Ph.D., Vice President Research, Dutalys GmbH Jon Ellis, Ph.D., Vice President, Business Development, Biopharmaceutical R&D and Platform Engineering Bispecific Antibodies Technology & Science, GlaxoSmithKline ImmTACS: a Novel Class of Bi-specifics for Cancer Stephen Megit, Ph.D., Senior Business Development Manager, Immunocore Ltd. Richard Harkins, Ph.D., Principal Scientist, Global Drug Discovery, Bayer Healthcare Pharmaceuticals A Novel Strategy to Engineer Agonists and Antagonists to Complex Membrane oncology stream Robert Hayes, Ph.D., Vice President & Venture Leader, Janssen R & D Targets Utilizing V(D)J Recombination in a Mammalian Cell Margaret Karow, Ph.D., Executive Director, Protein Sciences, Amgen, Inc. Michael Gallo, President, Innovative Targeting Solutions Antibodies for Cancer Therapy Nilesh Kumar, Ph.D., Merck Serono The MPS™ Platform for Discovery of Antibodies against Difficult Membrane Protein Luke Li, M.D., Executive Director, Head, Global BioTherapeutic Technologies, Pfizer, Inc. Targets Bispecific Antibodies for Oncology Thomas Li, Ph.D., Senior Director, Technology, Roche Diagnostics Benjamin Doranz, Ph.D., President and CSO, Integral Molecular, Inc. Kia Motesharei, Ph.D., Vice President, Business Development & Alliance Management, Dyax Corp. Antibody-Drug Conjugates The Kymab Discovery Platform: Harnessing Human Antibody Diversity in vivo Hilde Revets, Ph.D., Senior Research Fellow, Technology, Ablynx NV Allan Bradley, Ph.D., CSO, Kymab Ltd. Janine Schuurman, Director, Strategic Research, GenMab BV expression stream Barry Springer, Ph.D., Head, External Research and Innovation,Biologics Research, Johnson & Johnson MeMo® + Spleen to Screen™ - The Platform for Human Therapeutic Bispecific Antibody and Antibody Combination Discovery Difficult to Express Proteins Jason Avery, Chief Business Officer, Merus BV Partial List of Confirmed Presentations Simple, Stable, Smart – The Kappa/Lambda-Body Next-Generation Bispecific Drug Antibody Discovery and Optimization: GMP-ready Human Antibodies for Therapeutic Optimizing Protein Expression Discovery Platform Applications David Slack, Head, Corporate & Business Development, NovImmune SA Volker Lang, Ph.D., Managing Director, AbCheck s.r.o. High-Throughput Protein Expression Development of Single Domain VNAR Therapeutics for Central Nervous System Single Domain Shark Antibodies and their Human Equivalent, i-bodies, Diseases as Novel Therapeutics Frank Walsh, Ph.D., CEO, Ossianix, Inc. analytical stream Michael Foley, Ph.D., Department of Biochemistry, Latrobe University; CSO, AdAlta Pty. Ltd. Tanibirumab Phase I Study and GBM/HCC Phase II Preparation and its Rationale Functional Diversity as the key to choice in Human Antibody Drug Discovery Characterization of Biotherapeutics Jin-San Yoo, Ph.D., President and CEO, PharmAbcine, Inc. Debbie Allen, Ph.D., Senior Director, Business Development, arGEN-X Development of Angiogenesis Inhibitors Targeting Pathways other than VEGF Biophysical Analysis of Biotherapeutics Affimers: Engineered Alternatives to Antibodies that Provide a Toolkit for Discovery and Charles Theuer, Ph.D., CEO, TRACON Pharmaceuticals, Inc. Dissection of Biological and Pathological Processes Paul Ko Ferrigno, Ph.D., Group Head, Discovery Technology, Avacta Group plc Deep Screening of the OMT OmniRat™ Repertoire Using CellSpot™ Single Cell Protein Aggregation and Stability Multiplexing Tribodies for Two-in-One Bispecific Antibody Fragments William Usinger, Ph.D., Vice President, R&D, Trellis Bioscience, LLC Nico Mertens, Ph.D., Director, Antibody Research, Biotecnol, Inc. safety stream Antibody Library Display on a Mammalian Virus Vector: Combining the Advantages of Fynomab Platform for the Generation of Unique Bispecific Biotherapeutics both Phage and Yeast Display into One Technology Immunogenicity for Regulatory Success Fabian Buller, Ph.D., Director, Business Development, Covagen AG Ernest Smith, Ph.D., CSO, Vaccinex, Inc. Fully Human VH Antibody Fragments from the Crescendo Mouse Platform Immunogenicity Prediction & Mitigation Mike Romanos, Ph.D., CEO, Crescendo Biologics Ltd. PK/PD of Antibody-Derived Molecules Alumni Discount purification stream Cambridge Healthtech Institute (CHI) appreciates your past participation at the PEGS Summit. Through support like yours, CHI has stay connected been able to build this event into a must attend for senior level decision makers. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registration rate. Just check off Purifying Antibodies and Recombinant Proteins the box marked Alumni Discount on the registration form to receive the discount! Please note: Our records must indicate you were an attendee of the PEGS Summit in the past in order to qualify. Protein Aggregation and Stability Sponsor & Exhibit Registration Organized by Cambridge Healthtech Institute 5 PEGSummit.com
  6. 6. Cover 15th Annual engineering stream Event-at-a-Glance Our Sponsors Phage and Yeast Display of Antibodies April 29-30, 2013 Hotel & Travel Short Courses and Recombinant Proteins Biologics Partnering forum MONDAY, APRIL 29 TUESDAY APRIL 30 , PHARMA-BIO PARTNERING FORUMS 7:00 am Conference Registration and Morning Coffee 8:00 am Registration and Morning Coffee engineering streamFocusing on the Right Partners 8:30 Chairperson’s Opening Remarks Novel Applications of Phage Display Phage and Yeast Display Gregory A. Weiss, Ph.D., Professor, Chemistry, Molecular Biology & Biochemistry, UC Irvine »» Keynote session 8:25 Chairperson’s Opening Remarks Engineering Antibodies 8:40 Using Phage to Discover New Things about Biology 8:30 Employing Phage Display as a Means to Interrogate Dynamic Structural States of James A. Wells, Ph.D., Professor and Chair, Pharmaceutical Chemistry, UCSF Force-Bearing Proteins in the Extracellular Matrix Thomas Barker, Ph.D., Associate Professor, Wallace H. Coulter Department of Biomedical Engineering, Engineering Bispecific Antibodies 9:10 Ubiquitin Variants as Potent Inhibitors and Activators of Enzymes in the Georgia Institute of Technology Ubiquitin Pathway 9:00 Targeting Glycans and Viral Glycoproteins with Synthetic Antibodies Sachdev Sidhu, Ph.D., Associate Professor, Banting and Best Department of Medical Research, oncology stream University of Toronto Jonathan R. Lai, Ph.D., Assistant Professor, Biochemistry, Albert Einstein College of Medicine 9:30 Directed Evolution of DNA Polymerases for Next- Generation Sequencing Antibodies for Cancer Therapy 9:40 Phage Protein-Targeted Cancer Nanomedicines Floyd E. Romesberg, Ph.D., Associate Professor, Chemistry, The Scripps Research Institute Valery Petrenko, Ph.D., Sc.D., Professor, Pathobiology, College of Veterinary Medicine, Auburn University Bispecific Antibodies for Oncology 10:10 Grand Opening Coffee Break in Exhibit Hall with Poster Viewing 10:00 Coffee Break in the Exhibit Hall with Poster Viewing Improving Developability of Proteins Deep Sequencing of Antibody Libraries Antibody-Drug Conjugates 11:10 Towards High-Affinity, Aggregation-Resistant Domain Antibodies by Design 10:45 Molecular Deconvolution of the Circulating Antibody Repertoire in Human Health and Disease Peter Tessier, Ph.D., Assistant Professor, Chemical & Biological Engineering, Ctr for Biotechnology & expression stream Interdisciplinary Studies, Rensselaer Polytechnic Institute George Georgiou, Ph.D., Professor, Molecular Genetics & Microbiology, University of Texas, Austin 11:40 Engineering Drug-Like Properties of Therapeutic Proteins 11:15 Deep Panning: Steps towards Probing the IgOme Difficult to Express Proteins Jonathan M. Gershoni, Ph.D., Cell Research and Immunology, Tel Aviv University Andrew Buchanan, Ph.D., Sr Scientist, Protein Engineering, MedImmune Ltd. Optimizing Protein Expression 12:10 pm Automated High-Throughput Antibody Discovery and Optimization 11:45 Deep Sequencing Analysis of Phage Libraries Christopher Smith, Ph.D., Scientific Consultant, Biologics, Genedata Inc. Ratmir Derda, Ph.D., Principal Investigator, Alberta Glycomics Centre; Assistant Professor, Department of Chemistry, University of Alberta, Edmonton High-Throughput Protein Expression 12:40 Luncheon Presentation I Sponsored by Sponsored by When Worlds Collide: Antibody Technologies 12:15 pm Discovery & Development of DX-2930: and GPCRs A Phage Display Case Study analytical stream Stefanie Urlinger, Ph.D., Director, Discovery Alliances & Technologies, MorphoSys AG Andrew Nixon, Ph.D., Vice President, Discovery Research, Dyax Corp. 12:45 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Characterization of Biotherapeutics 1:10 Luncheon Presentation II (Sponsorship Opportunity Available) or Lunch on Your Own Own Improving Developability of Proteins 1:15 Ice Cream Break in the Exhibit Hall Biophysical Analysis of Biotherapeutics 2:00 Chairperson’s Remarks Phage Improvements Protein Aggregation and Stability 2:05 Developability by Design 2:00 Chairperson’s Remarks K. Dane Wittrup, Ph.D., J.R. Mares Professor, Chemical Engineering & Bioengineering, Massachusetts Institute of Technology; Co-Founder, Adimab David C. Lowe, Ph.D., Fellow, R&D, MedImmune Ltd safety stream 2:35 Stability Engineering of the Human Antibody Repertoire Using Phage Display and 2:05 3CARD: Ultra-Fast Single Round Phage and Yeast Display Antibody Library X-Ray Crystallography Screening Using Coupled Enzyme Reactions Immunogenicity for Regulatory Success Daniel Christ, Ph.D., Group Leader, Immunology Department; Director, Therapeutic Antibody Harald Kolmar, Ph.D., Professor of Applied Biochemistry, TU Darmstadt Development, Garvan Institute of Medical Research Immunogenicity Prediction & Mitigation 2:35 Rapid, Multiplexed Microfluidic Phage Display 3:05 Discovery, Characterization, and Manufacturing of Next Generation ADC’s and Michael C. McAlpine, Ph.D., Assistant Professor, Chemical and Biological Engineering, Princeton Bispecific Antibodies by Cell Free Protein Synthesis University PK/PD of Antibody-Derived Molecules Christopher Thanos, Ph.D., Director, Protein Engineering, Sutro Biopharma, Inc. 3:05 Antibody Selections Performed on Live Cells that Express Challenging Membrane 3:35 Best Poster Presentation Protein Targets by dsDNA Display with Deep Sequencing Analysis purification stream Yan Chen, Ph.D., Sr VP Research & Development, X-BODY BioSciences , 4:05 Refreshment Break in the Exhibit Hall with Poster Viewing 3:35 Refreshment Break in the Exhibit Hall with Poster Viewing Purifying Antibodies and Recombinant Proteins 4:45 Problem Solving Breakout Discussions 4:15 - 5:30 PLENARY KEYNOTE PANEL - for details see page 2 5:45 - 6:45 Welcoming Reception in Exhibit Hall with Poster Viewing Protein Aggregation and Stability 5:30 Close of Conference Sponsor & Exhibit Registration Organized by Cambridge Healthtech Institute 6 PEGSummit.com
  7. 7. Cover 14th Annual engineering stream Event-at-a-Glance Our Sponsors Engineering Antibodies May 1-2, 2013 Hotel & Travel Short Courses Challenging Targets, Next-Generation Research Methods and Antibody Therapeutics for Autoimmune Diseases Biologics Partnering forum PHARMA-BIO WEDNESDAY, MAY 1 Antibodies Against Intracellular and Membrane Targets PARTNERING FORUMS engineering streamFocusing on the Right Partners 7:00 am Conference Registration 2:00 Chairperson’s Remarks Sponsored by Luis Pardo, Ph.D., Max-Planck Research Group Leader, AG Oncophysiology, Max-Planck Institute of 7:45 Breakfast Presentation Experimental Medicine, Germany Phage and Yeast Display OmniRat and OmniMouse – Naturally Optimized Human Antibodies MT Roland Buelow, Ph.D., CEO, Open Monoclonal Technology, Inc. 2:05 Bifunctional TRAIL Antibodies Targeting Kv10.1 Potassium Channels Induce Engineering Antibodies Selective Apoptosis of Tumor Cells Structural and Sequencing Methods for Antibody Luis Pardo, Ph.D., Max-Planck Research Group Leader, AG Oncophysiology, Max-Planck Institute of Experimental Medicine, Germany Engineering Bispecific Antibodies Screening and Design 2:35 Rapid and Reliable Characterization of Fabs for Structural Analysis of an ABC 8:30 Chairperson’s Opening Remarks Transporter Susanne Gräslund, Ph.D., Principal Investigator, Biotechnology, Structural Genomics Consortium, Canada oncology stream JungMin Kim, Ph.D., Postdoctoral Scholar, Pharmaceutical Chemistry, University of California, 8:40 A Family-Based Approach to Study Proteins Involved in Epigenetic Signaling San Francisco Antibodies for Cancer Therapy Susanne Gräslund, Ph.D., Principal Investigator, Biotechnology, Structural Genomics Consortium, Canada 3:05 The Selexis SURE CHO-Mplus™ Library: Next Generation Sponsored by 9:10 Functional Single-Cell Hybridoma Screening Using Droplet-Based Microfluidics Innovation for Addressing Difficult-to-Express Proteins Bispecific Antibodies for Oncology Christoph Merten, Ph.D., Group Leader, Principal Investigator, Genome Biology Unit, European Andrew Sanford, Vice President, Business Development, Selexis, Inc. Molecular Biology Laboratory, Germany 3:35 Refreshment Break in the Exhibit Hall with Poster Viewing Antibody-Drug Conjugates 9:40 Molecular Computational Tools for Designing and Screening of Stable Antibodies 4:20 Problem Solving Breakout Discussions Neeraj J. Agrawal, Ph.D., Postdoctoral Associate, Chemical Engineering, Massachusetts Institute of Technology 5:20 - 6:30 Networking Reception in the Exhibit Hallwith Poster Viewing expression stream 10:10 Coffee Break in the Exhibit Hall with Poster Viewing Difficult to Express Proteins THURSDAY MAY 2 , Antibody Mixtures and Combinations 7:45 am Breakfast Presentation Sponsored by Optimizing Protein Expression 11:10 Simultaneous Inhibition of EGFR, HER2 and HER3 by an Antibody Mixture Advanced Structural Modeling with Schrödinger’s Biologics Suite (Pan-HER) Provides Broad and Potent Tumor Inhibition David A. Pearlman, Ph.D., Senior Principal Scientist, Schrodinger High-Throughput Protein Expression Johan Lantto, Ph.D., Principal Scientist, Project Leader, Symphogen A/S, Denmark Clinical and Preclinical Results for 11:40 Mechanisms of Action of MM-151, a Triobody™ Targeting EGFR: Has EGFR Met Its Match? Antibody Therapeutics for Autoimmune Diseases analytical stream Jeffrey. D. Kearns, Ph.D., Senior Scientist, MM-151, Merrimack Pharmaceuticals, Inc. 8:30 Chairperson’s Opening Remarks Sam Wu, Ph.D., Senior Scientist, Biologics Research, Janssen R&D Characterization of Biotherapeutics New Technologies for Antibody Engineering Sponsored by 8:35 From Structural Insights to Functional Mechanisms: Antibody Interaction 12:10 pm A Uniform Framework for Computer-Aided Biophysical Analysis of Biotherapeutics Biologics Design Mapping in Toll-like Receptor 3 Therapeutic Discovery Sam Wu, Ph.D., Senior Scientist, Biologics Research, Janssen R&D Christopher R. Corbeil, Ph.D., Research Scientist, Chemical Computing Group Protein Aggregation and Stability Sponsored by 9:05 Targeting the BLyS/BAFF Pathway: Will Important Differences Emerge among 12:40 Luncheon Presentation I: Addressing Challenges in Different Inhibitors? Synthetic Antibody Design Using Combinatorial Libraries William Stohl, M.D., Ph.D., Professor of Medicine, Division of Rheumatology, Keck School of Medicine, safety stream Chris Ullman, Ph.D., CSO, Isogenica Ltd. University of Southern California Sponsored by 1:10 Luncheon Presentation II: Multipass Membrane Protein 9:35 Epratuzumab, a Humanized Monoclonal Antibody Targeting the B Cell Receptor Immunogenicity for Regulatory Success Monoclonal Antibodies by DNA Immunization and High Throughput Flow CD22 for the Treatment of Systemic Lupus Erythematosus (SLE) Cytometry Screening Tony Shock, Ph.D., Director, Immunology Portfolio, UCB, United Kingdom Immunogenicity Prediction & Mitigation James W. Stave, Ph.D., CSO, SDIX 10:05 Coffee Break in the Exhibit Hall with Poster Viewing 1:40 Session Break PK/PD of Antibody-Derived Molecules 11:05 Mechanism of Action (MOA) of Daclizumab in Multiple Sclerosis (MS) Bibiana Bielekova, M.D., Chief, Neuroimmunological Diseases Unit, Neuroimmunology Branch, NINDS, National Institutes of Health purification stream 11:35 Simultaneous Engineering and Epitope Mapping in Order to Introduce Species Crossreactivity in a Therapeutic Antibody Purifying Antibodies and Recombinant Proteins Francois Rousseau, Ph.D., Head, Antibody Engineering, Research, Novimmune SA, Switzerland Protein Aggregation and Stability 12:05 pm Close of Conference Sponsor & Exhibit Registration Organized by Cambridge Healthtech Institute 7 PEGSummit.com
  8. 8. Cover 4th Annual engineering stream Event-at-a-Glance Our Sponsors Engineering Bispecific Antibodies May 2-3, 2013 Hotel & Travel Short Courses The Future of Antibody Development Biologics Partnering forum PHARMA-BIO PARTNERING THURSDAY, MAY 2 11:50 Chemically Programmed Bispecific Antibodies that Recruit and Activate T Cells FORUMS engineering streamFocusing on the Right Partners Christoph Rader, Ph.D., Associate Professor, Department of Cancer Biology and Department of 12:30 pm Conference Registration Molecular Therapeutics, The Scripps Research Institute, Scripps Florida Phage and Yeast Display Opening Session 12:20 pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own Engineering Antibodies 1:30 Chairperson’s Remarks 12:50 Session Break Engineering Bispecific Antibodies »» Keynote Presentation 1:40 Innovative Designs Ideas for Novel Targets and Target Pairs for Bispecific Antibody Approaches William R. Strohl, Ph.D., Vice President, Biologics Research, Janssen Pharmaceuticals, Inc. 1:35 Chairperson’s Opening Remarks oncology stream 2:10 Symmetry Breaking: Bispecific Antibodies, the Beginnings, and 50 Years On 1:40 Novel Formats for Fc-Containing Bispecifics Gert Riethmüller, M.D., Institute for Immunology Ludwig-Maximilians-Universität Gregory L. Moore, Ph.D., Senior Scientist, Protein Engineering, Xencor, Inc. Antibodies for Cancer Therapy 2:40 Designing and Engineering Azymetric™ Antibodies Towards Solving the “Light 2:10 An Innovative and Generic Route to Generate Bispecific Antibodies Monovalent Bispecific Antibodies for Oncology Chain Problem” for each Antigen in Conventional IgG Format Adam Corper, Ph.D., Scientist, Protein Engineering, Zymeworks Nazzareno Dimasi, Ph.D., Senior Scientist, Antibody Discovery & Protein Engineering, MedImmune Antibody-Drug Conjugates 3:10 Refreshment Break in the Exhibit Hall with Poster Viewing 2:40 Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair 4:00 Problem Solving Breakout Discussions Jaume Pons, Ph.D., Senior Vice President, CTO, Biotech Unit R&D Group; CSO, Rinat-Pfizer, Inc. expression stream 5:00 End of Day Indications Outside Oncology Difficult to Express Proteins FRIDAY, MAY 3 3:10 A Bispecific Multi-Mechanistic mAb Approach for a Serious Bacterial Pathogen Charles (Ken) Stover, Ph.D., Senior Director, Discovery Infectious Disease, MedImmune Optimizing Protein Expression 7:45 am Continental Breakfast in the Exhibit Hall with Poster Viewing 3:40 Antibody Fragment Phamacokinetics in the Eye and Implications for Bispecific Novel Targets Therapeutics High-Throughput Protein Expression Justin Scheer, Ph.D., Scientist, Protein Chemistry, Genentech, Inc. 8:30 Chairperson’s Opening Remarks 4:10 Close of Conference analytical stream 8:35 Novel Tumor-Targeted, Engineered IL-2 Variant (IL-2v)-Based Immunocytokines for Immunotherapy of Cancer Characterization of Biotherapeutics Christian Klein, Ph.D., Discovery Oncology oDTA, Pharma Research and Early Development (pRED), Roche Glycart AG Biophysical Analysis of Biotherapeutics 9:05 Inducing Memory Immune Responses with Bispecific Antibody Infusions Lawrence Lum, M.D., D.Sc., Professor of Immunology & Microbiology & Scientific Director, Immunotherapy & BMT, Karmanos Cancer Institute Protein Aggregation and Stability 9:35 Improving Chronic Wound Healing with Self-Signaling Bispecific Antibodies for Bacterial Detection safety stream D. Jason Riley, Ph.D., Department of Materials, Imperial College London 10:05 Coffee Break in the Exhibit Hall with Poster Viewing; Poster Award & Raffle Immunogenicity for Regulatory Success Drawing Immunogenicity Prediction & Mitigation Optimizing Drug-Like Properties 10:50 Efficient Generation of Stable Bispecific IgG1 by Controlled PK/PD of Antibody-Derived Molecules Fab-arm Exchange Janine Schuurman, Ph.D., Director, Strategic Research, Genmab BV purification stream 11:20 The Adimab Platform and its Utility for Discovering Bispecific Antibodies: Do Yeast Based Discovery Platforms Yield More Developable Molecular Entities? Purifying Antibodies and Recombinant Proteins Robert Mabry, Ph.D., Associate Director, Antibody Discovery and Bispecific Engineering, Adimab, LLC Protein Aggregation and Stability Sponsor & Exhibit Registration Organized by Cambridge Healthtech Institute 8 PEGSummit.com
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×